Moderna, Inc.

NASDAQ:MRNA

Biotechnology

Healthcare
$196.79 +4.01%

+$2.48 today

Market cap
$79.63B
Beta
1.03
P/E (TTM)
-7.9
EPS (TTM)
-$8.09
52W Low $22.28High $67.74

Volume 6.91M

Average 6.53M

MRNA Cash & Equivalents

Cash on hand and highly liquid investments that can be converted to cash almost immediately.

Moderna, Inc.NASDAQ: MRNA

Cash & Equivalents · Q3 FY2026 · quarter ended Sep 2026

Cash & equivalents rises 5.6% from a year ago

Cash & equivalents stood at $1.2B at the end of Q3 FY2026, up 5.6% from a year earlier and down 30.6% from the prior quarter. Over 3 fiscal years it compounded at -6.8% a year.

Context

  • Cash & equivalents amounted to 8.9% of total assets at the end of Q3 FY2026, down 0.5 pp from a year earlier.
  • Cash & equivalents increased in 1 of the last 3 fiscal years.

What to watch

Whether cash & equivalents keeps rising in the next quarterly balance sheet after a +5.6% change from a year earlier.

Sources:Balance SheetText generated from reported figures; not investment advice.

Latest quarterSep 2026
$1.2B-30.6% QoQ
Last fiscal yearDec 2025
$2.6B+34.7% YoY
Year agoSep 2025
$1.13B+5.6% since
Cash & Equivalents past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+5.6%——
1 year+34.7%——
3-year CAGR-6.8%——
5-year CAGR——
10-year CAGR——

Cash & Equivalents history

USD · from the balance sheet

Latest · FY2025
2.6B USD
Year-over-year change
+34.7%
4-year CAGR
-21.5%

Cash & Equivalents vs competitors

How MRNA compares with its peers on the latest reported figures

  • Peers report in different currencies, so cash & equivalents is compared through growth and share of total assets rather than absolute size.
  • Its year-over-year change of +5.6% is the highest of 10, against a peer median of -31.1%.
  • Cash & equivalents amounts to 8.9% of total assets for MRNA, versus a peer median of 26.9%.
MRNA Competitors
Cash & Equivalents for MRNA and competitors
Company Period Latest balance YoY 3-year CAGR% of assets
BNTXBioNTech SEJun 2026€9.74B EUR-5.2%-17.9%47.9%
GSKGSK plcJun 2026£3.09B GBP-37.4%-3.1%5.0%
MRNAModerna, Inc.Sep 2026$1.2B USD+5.6%-6.8%8.9%
PFEPfizer Inc.Jun 2026$976M USD-40.4%+40.0%0.5%
VIRVir Biotechnology, Inc.Mar 2026$276.09M USD+0.9%-34.9%26.9%
NVAXNovavax, Inc.Mar 2026$228.36M USD-13.3%-43.5%21.9%
ARCTArcturus Therapeutics Holdings Inc.Mar 2026$211.38M USD-2.6%-16.2%86.1%
PCVXVaxcyte, Inc.Jun 2026$183.19M USD-40.3%-40.7%5.8%
VALNValneva SEMar 2026€105.37M EUR-31.1%-27.6%28.3%
INOInovio Pharmaceuticals, Inc.Mar 2026$26.27M USD-34.2%-1.5%52.8%
Peer median (excluding MRNA) —-31.1%-17.9%26.9%

Competitors are the stored peer set for MRNA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Balance Sheet

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Cash & Equivalents6.85B3.21B2.91B1.93B2.6B
Short-term Investments3.88B6.7B5.7B5.1B3.2B
Net Receivables3.32B1.69B1.08B592M284M
Inventory1.44B949M202M117M153M
Other Current Assets26M44M88M58M45M
Total Current Assets16.07B13.43B10.33B8.1B6.54B
Property, Plant & Equipment (Net)1.38B2.14B2.66B2.96B2.85B
Goodwill0052M52M52M
Intangible Assets0044M40M45M
Long-term Investments6.84B8.36B4.74B2.51B2.34B
Tax Assets326M982M81M81M81M
Other Non-current Assets46M946M523M407M421M
Total Non-current Assets8.6B12.43B8.1B6.04B5.79B
Total Assets24.67B25.86B18.43B14.14B12.34B
Account Payables302M487M520M405M317M
Short-term Debt00000
Tax Payables876M48M63M3M0
Deferred Revenue6.25B2.04B568M153M99M
Other Current Liabilities140M243M842M863M1.57B
Total Current Liabilities9.13B4.92B3.02B2.21B1.99B
Long-term Debt00001.24B
Deferred Tax Liabilities00000
Deferred Revenue (Non-current)615M673M83M58M153M
Other Non-current Liabilities76M135M256M267M(368M)
Total Non-current Liabilities1.4B1.81B1.56B1.04B1.7B
Total Liabilities10.52B6.74B4.57B3.24B3.69B
Common Stock00000
Retained Earnings9.96B18.32B13.61B10.05B7.22B
Accumulated OCI(24M)(370M)(123M)(10M)45M
Other Stockholders Equity00000
Minority Interest00000
Total Equity14.15B19.12B13.85B10.9B8.65B
Total Debt916M1.2B1.24B747M1.92B
Net Debt(5.93B)(2.01B)(1.66B)(1.18B)(679M)

Moderna, Inc.

NASDAQ:MRNA

Intrinsic Alpha fair value

Locked

Current Price

$196.79

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.